Dawson James reiterated their buy rating on shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) in a report issued on Wednesday morning. The brokerage currently has a $9.00 target price on the stock.

Several other brokerages also recently weighed in on TNXP. Aegis began coverage on shares of Tonix Pharmaceuticals Holding Corp. in a research report on Monday, June 26th. They set a buy rating and a $10.00 price target for the company. Drexel Hamilton began coverage on shares of Tonix Pharmaceuticals Holding Corp. in a research report on Tuesday. They set a buy rating for the company. Finally, Roth Capital raised shares of Tonix Pharmaceuticals Holding Corp. from a neutral rating to a buy rating and set a $6.00 price target for the company in a research report on Friday, August 18th. They noted that the move was a valuation call. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock has an average rating of Buy and a consensus price target of $8.33.

Shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ TNXP) opened at 3.75 on Wednesday. Tonix Pharmaceuticals Holding Corp. has a 52-week low of $2.85 and a 52-week high of $28.00. The firm’s market capitalization is $28.16 million. The stock has a 50 day moving average price of $3.75 and a 200-day moving average price of $3.39.

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) last announced its quarterly earnings results on Monday, August 14th. The company reported ($0.65) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.78) by $0.13. Equities analysts forecast that Tonix Pharmaceuticals Holding Corp. will post ($3.02) EPS for the current year.

TRADEMARK VIOLATION NOTICE: This piece of content was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another site, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/08/26/dawson-james-reaffirms-buy-rating-for-tonix-pharmaceuticals-holding-corp-tnxp.html.

In other news, CEO Seth Lederman purchased 20,000 shares of Tonix Pharmaceuticals Holding Corp. stock in a transaction that occurred on Thursday, August 17th. The stock was bought at an average price of $3.00 per share, with a total value of $60,000.00. Following the completion of the transaction, the chief executive officer now directly owns 11,166 shares of the company’s stock, valued at $33,498. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Ernest Mario sold 6,105 shares of the firm’s stock in a transaction that occurred on Friday, June 30th. The shares were sold at an average price of $4.28, for a total transaction of $26,129.40. Following the sale, the director now directly owns 63,073 shares of the company’s stock, valued at approximately $269,952.44. The disclosure for this sale can be found here. Insiders have purchased 50,000 shares of company stock valued at $188,050 in the last three months. 4.00% of the stock is owned by insiders.

Several large investors have recently made changes to their positions in the stock. B. Riley Financial Inc. purchased a new stake in shares of Tonix Pharmaceuticals Holding Corp. during the second quarter valued at $1,637,000. Vanguard Group Inc. increased its stake in Tonix Pharmaceuticals Holding Corp. by 28.8% in the second quarter. Vanguard Group Inc. now owns 184,377 shares of the company’s stock worth $799,000 after buying an additional 41,264 shares during the period. Citadel Advisors LLC bought a new stake in Tonix Pharmaceuticals Holding Corp. during the first quarter worth approximately $119,000. Dialectic Capital Management LP bought a new stake in Tonix Pharmaceuticals Holding Corp. during the first quarter worth approximately $187,000. Finally, Renaissance Technologies LLC increased its stake in Tonix Pharmaceuticals Holding Corp. by 108.4% in the fourth quarter. Renaissance Technologies LLC now owns 774,603 shares of the company’s stock worth $364,000 after buying an additional 402,898 shares during the period. 17.50% of the stock is owned by institutional investors.

Tonix Pharmaceuticals Holding Corp. Company Profile

Tonix Pharmaceuticals Holding Corp., a clinical-stage pharmaceutical company, engages in developing pharmaceutical products for central nervous system disorders. The company’s lead program focuses on post-traumatic stress disorder (PTSD) that is characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and economic burden.

Analyst Recommendations for Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)

Receive News & Stock Ratings for Tonix Pharmaceuticals Holding Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals Holding Corp. and related stocks with our FREE daily email newsletter.